Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Inclusion Criteria: * Post-menopausal women (at least 5 years after natural / surgical menopause). * Patients on treatment with alendronate 70mg tablets or alendronate 70mg effervescent tablets for 6-8 months and who will be continued to be treated for a minimum of 12 months. * Available BTMs (s-CTX), biochemistry (calcium, phosphate, 25-OH vit D, PTH, creatinine) and DXA (lumbar spine, total hip and femoral neck) at the initiation of the treatment. * Ability to sign an informed patient consent Exclusion Criteria: * Patients who had received a prior osteoporosis treatment with anti-resorptive drugs (bisphosphonate or denosumab) or teriparatide before starting alendronate 70 mg. * Any secondary cause of osteoporosis including current treatment with glucocorticoids or aromatase inhibitors, inflammatory disorders, malabsorption * Metabolic or cancer bone disease * Contra-indications to bisphosphonates according to product labelling * Known or suspected allergy to study product(s) or related products * Inability to sign an informed consent * Previous participation in this study